Drug Profile


Alternative Names: DDP 733; MKC 733

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Mitsubishi Chemical
  • Developer Dynogen Pharmaceuticals; Edusa Pharmaceuticals; Mitsubishi Chemical
  • Class Gastrokinetics; Irritable bowel syndrome therapies; Laxatives; Quinuclidines; Small molecules
  • Mechanism of Action Serotonin 3 receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Constipation; Dyspepsia; Gastro-oesophageal reflux; Irritable bowel syndrome; Reflux oesophagitis

Most Recent Events

  • 12 Jul 2010 Phase-II clinical trials in Gastro-oesophageal reflux in USA (PO)
  • 22 May 2008 Final safety and efficacy data from a phase IIa (IBS-c) trial in Irritable bowel syndrome presented at the Digestive Disease Week 2008 (DDW-2008) ,
  • 09 Nov 2007 Phase-II clinical trials in Irritable bowel syndrome in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top